Epm2b gene mutations associated with lafora's disease
CA 2534382 C · Owner: Minassian, Berge A. · Inventors: Scherer, Stephen W.; Minassian, Berge A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described. EPM2B encodes a protein containing a zinc finder of the RING type in the N-terminal portion and 6 NHL-repeat domains in the C-terminal portion which is associated with Lafora's disease. Also described are , methods for detecting the presence or absence of a mutation in the EPM2B gene and methods for detecting the presence of or predisposition to, Lafora's , disease by detecting a mutation in the EMP2B gene or protein.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 30, 2004 and granted December 11, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 30, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 30, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.